South Dakota § 34-20B-20.2

South Dakota Statutes

§ 34-20B-20.2

Title 34PUBLIC HEALTH AND SAFETY

Ch. 34-20DRUGS AND SUBSTANCES CONTROL

This text of South Dakota § 34-20B-20.2 is published on Counsel Stack Legal Research, covering South Dakota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

S.D. Codified Laws § 34-20B-20.2 (2026).

Text

Xylazine--Permissible uses. Any material, compound, mixture, or preparation that contains xylazine is a Schedule III controlled drug or substance, except in the following cases:

(1)Dispensing, prescribing, or administering, to an animal, a drug containing xylazine that has been approved by the United States secretary of health and human services under 21 U.S.C. § 360b (January 1, 2024);

(2)Dispensing, prescribing, or administering xylazine to an animal that is permissible under 21 U.S.C. § 360b(a)(4) (January 1, 2024);

(3)Manufacturing, distributing, or using xylazine as an active pharmaceutical ingredient for manufacturing an animal drug:

(a)Approved under 21 U.S.C. § 360b (January 1, 2024); or (b) Issued an investigation use exemption under 21 U.S.C. § 360b(j) (January

Free access — add to your briefcase to read the full text and ask questions with AI

Xylazine--Permissible uses. Any material, compound, mixture, or preparation that contains xylazine is a Schedule III controlled drug or substance, except in the following cases: (1) Dispensing, prescribing, or administering, to an animal, a drug containing xylazine that has been approved by the United States secretary of health and human services under 21 U.S.C. § 360b (January 1, 2024); (2) Dispensing, prescribing, or administering xylazine to an animal that is permissible under 21 U.S.C. § 360b(a)(4) (January 1, 2024); (3) Manufacturing, distributing, or using xylazine as an active pharmaceutical ingredient for manufacturing an animal drug: (a) Approved under 21 U.S.C. § 360b (January 1, 2024); or (b) Issued an investigation use exemption under 21 U.S.C. § 360b(j) (January 1, 2024); (4) Manufacturing, distributing, or using a xylazine bulk chemical for pharmaceutical compounding by a licensed pharmacist or veterinarian; or (5) Any other use approved or permissible under 21 U.S.C. § 301, et seq. (January 1, 2024).